Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS), Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, United States.
Front Immunol. 2021 Aug 30;12:737428. doi: 10.3389/fimmu.2021.737428. eCollection 2021.
The mechanisms underlying the major histocompatibility complex class II (MHCII) type 1 diabetes (T1D) association remain incompletely understood. We have previously shown that thymocytes expressing the highly diabetogenic, I-A-restricted 4.1-T-cell receptor (TCR) are MHCII-promiscuous, and that, in MHCII-heterozygous mice, they sequentially undergo positive and negative selection/Treg deviation by recognizing pro- and anti-diabetogenic MHCII molecules on cortical thymic epithelial cells and medullary hematopoietic antigen-presenting cells (APCs), respectively. Here, we use a novel autoantigen discovery approach to define the antigenic specificity of this TCR in the context of I-A. This was done by screening the ability of random epitope-GS linker-I- chain fusion pools to form agonistic peptide-MHCII complexes on the surface of I- chain-transgenic artificial APCs. Pool deconvolution, I-A-binding register-fixing, TCR contact residue mapping, and alanine scanning mutagenesis resulted in the identification of a 4.1-TCR recognition motif XL(G/A)XEXE(D/E)X that was shared by seven agonistic hybrid insulin peptides (HIPs) resulting from the fusion of several different chromogranin A and/or insulin C fragments, including post-translationally modified variants. These data validate a novel, highly sensitive MHCII-restricted epitope discovery approach for orphan TCRs and suggest thymic selection of autoantigen-promiscuous TCRs as a mechanism for the murine T1D-I-A-association.
主要组织相容性复合体 II 类(MHCII)1 型糖尿病(T1D)关联的机制仍不完全清楚。我们之前已经表明,表达高度致糖尿病的 I-A 限制性 4.1-T 细胞受体(TCR)的胸腺细胞是 MHCII 混杂的,并且在 MHCII 杂合子小鼠中,它们通过分别识别皮质胸腺上皮细胞和髓质造血抗原呈递细胞(APCs)上的促糖尿病和抗糖尿病 MHCII 分子,依次经历阳性和阴性选择/Treg 偏差。在这里,我们使用一种新的自身抗原发现方法来定义该 TCR 在 I-A 背景下的抗原特异性。这是通过筛选随机表位-GS 接头-I- 链融合池在 I- 链转基因人工 APC 表面形成激动肽-MHCII 复合物的能力来完成的。池解卷积、I-A 结合注册固定、TCR 接触残基映射和丙氨酸扫描诱变导致鉴定出一个 4.1-TCR 识别基序 XL(G/A)XEXE(D/E)X,该基序与七个激动肽混合胰岛素(HIP)共享,这些 HIP 是由几种不同的嗜铬粒蛋白 A 和/或胰岛素 C 片段融合而成的,包括翻译后修饰的变体。这些数据验证了一种新的、高度敏感的 MHCII 限制性表位发现方法,适用于孤儿 TCR,并表明自身抗原混杂 TCR 的胸腺选择是小鼠 T1D-I-A 关联的一种机制。